423 related articles for article (PubMed ID: 16729730)
21. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
[TBL] [Abstract][Full Text] [Related]
22. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
Deng Z; Chuaqui C; Singh J
J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
[TBL] [Abstract][Full Text] [Related]
23. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
25. Comparison of structure- and ligand-based virtual screening protocols considering hit list complementarity and enrichment factors.
Krüger DM; Evers A
ChemMedChem; 2010 Jan; 5(1):148-58. PubMed ID: 19908272
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
27. Comparative assessment of scoring functions on a diverse test set.
Cheng T; Li X; Li Y; Liu Z; Wang R
J Chem Inf Model; 2009 Apr; 49(4):1079-93. PubMed ID: 19358517
[TBL] [Abstract][Full Text] [Related]
28. Protein-ligand docking accounting for receptor side chain and global flexibility in normal modes: evaluation on kinase inhibitor cross docking.
May A; Zacharias M
J Med Chem; 2008 Jun; 51(12):3499-506. PubMed ID: 18517186
[TBL] [Abstract][Full Text] [Related]
29. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
[TBL] [Abstract][Full Text] [Related]
30. Beyond the virtual screening paradigm: structure-based searching for new lead compounds.
Schlosser J; Rarey M
J Chem Inf Model; 2009 Apr; 49(4):800-9. PubMed ID: 19354328
[TBL] [Abstract][Full Text] [Related]
31. Protein structures in virtual screening: a case study with CDK2.
Thomas MP; McInnes C; Fischer PM
J Med Chem; 2006 Jan; 49(1):92-104. PubMed ID: 16392795
[TBL] [Abstract][Full Text] [Related]
32. Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening.
Rastelli G; Degliesposti G; Del Rio A; Sgobba M
Chem Biol Drug Des; 2009 Mar; 73(3):283-6. PubMed ID: 19207463
[TBL] [Abstract][Full Text] [Related]
33. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
34. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
35. Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring models.
Cotesta S; Giordanetto F; Trosset JY; Crivori P; Kroemer RT; Stouten PF; Vulpetti A
Proteins; 2005 Sep; 60(4):629-43. PubMed ID: 16028223
[TBL] [Abstract][Full Text] [Related]
36. Deciphering ligand dependent degree of binding site closure and its implication in inhibitor design: A modeling study on human adenosine kinase.
Bhutoria S; Ghoshal N
J Mol Graph Model; 2010 Feb; 28(6):577-91. PubMed ID: 20089430
[TBL] [Abstract][Full Text] [Related]
37. kinDOCK: a tool for comparative docking of protein kinase ligands.
Martin L; Catherinot V; Labesse G
Nucleic Acids Res; 2006 Jul; 34(Web Server issue):W325-9. PubMed ID: 16845019
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
Park H; Chi O; Kim J; Hong S
J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
[TBL] [Abstract][Full Text] [Related]
39. Postprocessing of protein-ligand docking poses using linear response MM-PB/SA: application to Wee1 kinase inhibitors.
Wichapong K; Lawson M; Pianwanit S; Kokpol S; Sippl W
J Chem Inf Model; 2010 Sep; 50(9):1574-88. PubMed ID: 20712342
[TBL] [Abstract][Full Text] [Related]
40. High-throughput docking as a source of novel drug leads.
Alvarez JC
Curr Opin Chem Biol; 2004 Aug; 8(4):365-70. PubMed ID: 15288245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
